



Securities Code: 4523

FY 2022 (Ending March 31, 2023)
First Quarter Financial Results

Reference Data

August 5, 2022

Eisai Co., Ltd.

For Inquiries:

Public Relations: TEL +81-(0)3-3817-5120

Investor Relations: TEL +81-(0)70-8688-9685

<https://www.eisai.com/>

Forward-Looking Statements and Risk Factors

Materials and information provided in this announcement include current forecasts, targets, evaluations, estimates, assumptions that are accompanied by risks, and other matters that are based on uncertain factors. Accordingly, it is possible that actual results will deviate significantly from forecasts, etc., due to changes to a variety of factors. These risks and uncertainties include general industry and market conditions, fluctuation of interest rates and currency exchange rates, and other aspects of economic conditions in Japan and internationally.

Risks and uncertainties that could cause significant fluctuations in the results of the Group or have a material effect on investment decisions are as follows. However, these do not cover all of the risks and uncertainties faced by the Group, and it is possible that they will be affected in the future by other factors that cannot be foreseen, or are not deemed to be important, at this point in time.

These are judgments as of the time of the announcement, and statements in the text regarding the future are not guarantees that they will occur or be achieved.

Risks factors include risks related to management based on the Corporate Concept, risks related to maximizing the value of next-generation Alzheimer's Disease treatments, risks related to maximizing the value of Lenvima, risks related to partnership model, risks related to digital transformation, risks related to uncertainties in new drug development, risks related to side effects, risks related to product quality and stable supply, risks related to intellectual property, risks related to litigations, risks related to data reliability, risks related to trends to contain medical costs, risks related to succession, risks related to acquiring and developing human resources, risks related to information security, risks related to COVID-19, risks related to climate change, risks related to impairment of goodwill and intangible assets.

This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.

Contents

1. Consolidated Statement of Income	-----	1
2. Segment Information	-----	2
3. Financial Results by Reporting Segment	-----	3
4. Revenue from Major Products	-----	7
5. Revenue Forecasts by Reporting Segment	-----	9
6. Consolidated Statement of Comprehensive Income	-----	10
7. Consolidated Statement of Cash Flows	-----	11
8. Capital Expenditures, Depreciation and Amortization	-----	12
9. Consolidated Statement of Financial Position	-----	12
10. Changes in Quarterly Results	-----	14
11. Major R&D Pipeline	-----	17

Currency Exchange Rates

		US (USD/JPY)	EU (EUR/JPY)	UK (GBP/JPY)	China (RMB/JPY)
FY 2021 Q1	Quarterly Average Rate	109.49	131.96	153.20	16.95
	Quarter End Rate	110.58	131.58	153.16	17.11
FY 2021	Yearly Average Rate	112.37	130.56	153.55	17.51
	Year End Rate	122.39	136.70	160.89	19.26
FY 2022 Q1	Quarterly Average Rate	129.57	138.11	162.96	19.57
	Quarter End Rate	136.68	142.67	165.71	20.38
FY 2022	Forecast Rate	125.00	130.00	151.50	19.00

* Eisai Co., Ltd. ("the Company") discloses its consolidated financial statements in accordance with the International Financial Reporting Standards (IFRS).

* Eisai Group's ("the Group") business is comprised of pharmaceutical business and other business. The pharmaceutical business is organized into the following six reporting segments in this report: Japan, Americas (North America), China, EMEA (Europe, the Middle East, Africa, Russia, and Oceania), Asia and Latin America (primarily South Korea, Taiwan, India, ASEAN, Central and South America), and OTC and others (Japan). Effective from April 1, 2022, Hong Kong has been changed from Asia and Latin America pharmaceutical business to China pharmaceutical business. This change has been reflected in the segment information for FY 2021.

* As described on page 18 of Consolidated Financial Report, Supplemental Materials, the figures for FY2021 have been revised for retroactive application due to changes in accounting policies.

* All amounts are rounded to the nearest specified unit.

1. Consolidated Statement of Income

(billions of yen)

	FY 2021				FY 2022				FY 2022	
	Q1	Ratio (%)	Full year	Ratio (%)	Q1	Ratio (%)	YOY (%)	Diff.	Full year forecast	Ratio (%)
Revenue	198.9	100.0	756.2	100.0	184.3	100.0	92.6	(14.6)	700.0	100.0
Cost of sales	39.2	19.7	174.8	23.1	47.4	25.7	120.8	8.2	160.5	22.9
Gross profit	159.6	80.3	581.4	76.9	136.9	74.3	85.7	(22.8)	539.5	77.1
Selling, general and administrative expenses	74.8	37.6	366.4	48.5	92.3	50.1	123.4	17.5	339.0	48.4
Selling expenses	32.4	16.3	190.4	25.2	50.2	27.3	155.0	17.8	—	—
Personnel expenses	22.7	11.4	101.3	13.4	24.0	13.0	105.9	1.3	—	—
Administrative and other expenses	19.7	9.9	74.8	9.9	18.1	9.8	91.6	(1.7)	—	—
Research and development expenses	41.8	21.0	171.7	22.7	38.5	20.9	92.1	(3.3)	159.0	22.7
Other income	13.4	6.8	14.6	1.9	2.5	1.3	18.3	(11.0)	13.5	1.9
Other expenses	1.1	0.6	4.1	0.5	1.1	0.6	94.4	(0.1)	—	—
Operating profit	55.3	27.8	53.7	7.1	7.4	4.0	13.4	(47.9)	55.0	7.9
Financial income	0.7	0.4	2.4	0.3	2.7	1.5	359.7	1.9	—	—
Financial costs	0.4	0.2	1.7	0.2	0.4	0.2	108.8	0.0	—	—
Profit before income taxes	55.7	28.0	54.5	7.2	9.7	5.3	17.4	(46.0)	56.5	8.1
Income taxes	13.5	6.8	8.7	1.2	(18.2)	(9.9)	—	(31.7)	—	—
Profit for the period	42.3	21.2	45.7	6.0	28.0	15.2	66.2	(14.3)	58.0	8.3
Profit for the period attributable to										
Owners of the parent	42.1	21.2	48.0	6.3	26.9	14.6	63.9	(15.2)	57.0	8.1
Non-controlling interests	0.1	0.1	(2.2)	(0.3)	1.1	0.6	746.1	0.9	—	—
Comprehensive income for the period	42.4	21.3	90.8	12.0	79.7	43.3	188.1	37.3		
Earnings per share (EPS, yen)	146.89		167.27		93.81				197.80	
Dividend per share (DPS, yen)	—		160.0		—				160.0	
Return on equity (ROE, %)	—		6.6		—				7.5	
Dividends on equity ratio (DOE, %)	—		6.3		—				6.1	

* Full year estimation for other income has had other expenses deducted from it.

* EPS: Earnings Per Share attributable to owners of the parent (basic).

Notes

Revenue	Significant growth of the anticancer agent Lenvima: 66.3 billion yen (the same period in previous fiscal year: 44.2 billion yen) Recording of an upfront payment from Bristol Myers Squibb under strategic collaboration for antibody drug conjugate MORAb-202: 49.6 billion yen in the same period of the previous fiscal year
Selling, general and administrative expenses	Recording of expenses regarding shared profit of Lenvima paid to Merck & Co., Inc., Rahway, NJ, USA.: 31.7 billion yen (the same period in previous fiscal year: 19.8 billion yen)
Research and development expenses	Controlling of the expenses through the partnership model (partner's burden: 17.5 billion yen (the same period in previous fiscal year: 10.8 billion yen)) including recording of reversal of 3.2 billion yen as regulatory milestone payments from Merck & Co., Inc., Rahway, NJ, USA due to obtaining approval for Lenvima's combination treatment for advanced renal cell carcinoma in Europe
Income taxes	Recording of a credit of income taxes due to recognition of losses on transferring of investments in subsidiaries for tax purposes following a repayment of paid-in capital from a U.S. subsidiary to the Company as part of the Group's capital policy to optimize the global allocation of cash
Exchange rate effects	Revenue: +15.56 billion yen, operating profit: -6.28 billion yen
Exchange rate sensitivity (annual effect of 1 yen depreciation in currency value)	Revenue (U.S. dollars: +1.66 billion yen, Euro: +0.31 billion yen, U.K. pounds: +0.09 billion yen, Chinese renminbi: +6.98 billion yen) Operating profit (U.S. dollars: -1.50 billion yen, Euro: +0.20 billion yen, U.K. pounds: -0.01 billion yen, Chinese renminbi: +3.59 billion yen)

* Of 110 million USD (for April 2022 - December 2022), which is the remaining amount of Eisai's share of Alzheimer's disease treatment ADUHELM related expenses capped at 335 million USD by the amendment of the collaboration agreements with Biogen Inc. in March 2022, 51 million USD is recorded in selling, general and administrative expenses, and research and development expenses in this period.

2. Segment Information

1) Revenue

(billions of yen)

	FY 2021		FY 2022		
	Q1	Full year	Q1	YOY (%)	CER YOY (%)
Pharmaceutical Business Total	147.2	626.3	181.3	123.2	112.8
Japan pharmaceutical business	49.6	214.0	57.5	115.8	115.8
Americas pharmaceutical business	38.3	172.0	53.1	138.5	117.1
United States	37.7	169.5	52.2	138.4	117.0
China pharmaceutical business	27.4	108.4	34.8	127.1	110.0
EMEA pharmaceutical business	14.1	59.3	18.1	128.1	118.0
Asia and Latin America pharmaceutical business	12.6	48.6	12.0	95.0	86.4
OTC and others	5.2	23.8	6.0	115.3	115.3
Other business	51.7	129.9	2.9	5.6	5.3
Consolidated revenue	198.9	756.2	184.3	92.6	84.8

* Indicates revenue from external customers.

* CER=Constant Exchange Rates

2) Profit by Reporting Segment

(billions of yen)

	FY 2021		FY 2022		
	Q1	Full year	Q1	YOY (%)	CER YOY (%)
Pharmaceutical Business Total	68.1	268.9	90.6	133.1	123.2
Japan pharmaceutical business	15.6	61.0	21.6	138.9	138.9
Americas pharmaceutical business	21.7	95.6	31.3	144.0	132.3
China pharmaceutical business	16.4	57.0	20.8	126.4	111.4
EMEA pharmaceutical business	8.1	30.1	10.2	127.1	112.1
Asia and Latin America pharmaceutical business	5.7	20.4	5.3	94.0	85.3
OTC and others	0.7	4.7	1.4	207.8	207.8
Other business	49.8	121.6	0.5	1.0	0.7
Research and development expenses	(41.8)	(171.7)	(38.5)	92.1	76.8
Group headquarters' management costs and other expenses [#]	(20.8)	(165.0)	(45.2)	217.2	184.7
Consolidated operating profit	55.3	53.7	7.4	13.4	24.8

[#] Includes the amount of profits and expenses shared under strategic collaborations with partners.

[#] As the co-development and co-promotion agreements on ADUHELM with Biogen Inc. were changed in March 2022, all relevant expenses (selling, general and administrative expenses) that the Company should share have been included in the "Group headquarters' management costs and other expenses" since April 1, 2022. In addition, gains and losses on sale of non-current assets have been included in the "Group headquarters' management costs and other expenses". As a result, these changes of the FY 2021 have been reflected in Segment Information.

3. Financial Results by Reporting Segment

1) Japan pharmaceutical business

(billions of yen)

	FY 2021		FY 2022	
	Q1	Full year	Q1	YOY (%)
Revenue	49.6	214.0	57.5	115.8
Segment profit	15.6	61.0	21.6	138.9
Japan prescription medicines - revenue from major products				
Fully human anti-TNF- α monoclonal antibody Humira	11.4	50.6	12.6	110.1
Insomnia treatment Dayvigo	1.9	12.7	5.3	285.2
Anticancer agent Lenvima	2.5	10.3	3.6	144.3
Peripheral neuropathy treatment Methycobal	2.4	10.8	2.7	111.5
Anticancer agent Halaven	2.0	8.3	2.2	113.6
Elemental diet Elental [#]	1.7	6.8	1.8	109.6
Chronic constipation treatment Goofice [#]	1.4	6.1	1.7	115.3
Proton pump inhibitor Pariet [#]	1.7	7.1	1.6	94.3
Antiepileptic agent Fycompa	1.2	5.4	1.6	126.0
Chronic constipation treatment Movicol [#]	1.1	4.9	1.6	139.7
Janus kinase inhibitor Jyseleca	0.1	1.5	1.3	979.3
Alzheimer's disease / Dementia with Lewy bodies treatment Aricept	1.8	6.9	1.2	69.4

* The revenue for Pariet includes the revenue for triple formulation packs for *Helicobacter pylori* eradication, Rabecure Pack 400/800 and Rabefine Pack.

[#] EA Pharma product

2) Americas pharmaceutical business (North America)

(billions of yen)

	FY 2021		FY 2022	
	Q1	Full year	Q1	YOY (%)
Revenue	38.3	172.0	53.1	138.5 <117.1>
United States	37.7	169.5	52.2	138.4 <117.0>
Segment profit	21.7	95.6	31.3	144.0 <132.3>
Americas - revenue from major products				
Anticancer agent Lenvima	24.4	116.5	38.5	157.8 <133.4>
United States	24.1	115.5	38.2	158.4 <133.8>
	[Millions USD] [220]	[1,028]	[295]	
Antiepileptic agent Fycompa	3.4	14.6	4.6	132.6 <112.2>
United States	3.3	14.1	4.4	132.6 <112.0>
	[Millions USD] [30]	[125]	[34]	
Anticancer agent Halaven	3.3	14.3	4.1	124.7 <105.5>
United States	3.2	14.0	4.0	124.6 <105.3>
	[Millions USD] [29]	[125]	[31]	
Insomnia Treatment Dayvigo	0.8	3.7	1.1	147.4 <125.6>
United States	0.7	3.2	0.9	126.3 <106.7>
	[Millions USD] [7]	[29]	[7]	
Antiepileptic agent Banzel	2.8	7.0	0.9	30.6 <25.9>
United States	2.8	6.7	0.8	28.3 <23.9>
	[Millions USD] [25]	[60]	[6]	

* YOY percentage: figures shown in angle brackets "< >" exclude the effects of foreign exchange fluctuations.

3) China pharmaceutical business

(billions of yen)

	FY 2021		FY 2022	
	Q1	Full year	Q1	YOY (%)
Revenue	27.4	108.4	34.8	127.1 <110.0>
Segment profit	16.4	57.0	20.8	126.4 <111.4>
China - revenue from major products				
Anticancer agent Lenvima	10.8	35.8	13.9	128.5 <111.3>
Peripheral neuropathy treatment Methycobal	3.3	12.7	4.4	132.8 <115.0>
Proton pump inhibitor Pariet	2.3	9.1	2.3	100.6 <87.1>
Liver disease / Allergic disease agents Stronger Neo-Minophagen C and Glycyron Tablets	2.3	9.5	2.0	85.9 <74.4>
Alzheimer's disease treatment Aricept	1.4	5.3	1.6	113.1 <98.0>
Antiepileptic agent Fycompa	0.2	1.2	0.6	234.9 <203.4>
Anticancer agent Halaven	0.9	1.6	0.6	58.5 <50.6>

* YOY percentage: figures shown in angle brackets "< >" exclude the effects of foreign exchange fluctuations.

4) EMEA pharmaceutical business (Europe, the Middle East, Africa, Russia and Oceania)

(billions of yen)

	FY 2021		FY 2022	
	Q1	Full year	Q1	YOY (%)
Revenue	14.1	59.3	18.1	128.1 <118.0>
Segment profit	8.1	30.1	10.2	127.1 <112.1>
EMEA - revenue from major products				
Anticancer agent Lenvima/Kispplx	4.8	21.8	8.1	167.1 <153.8>
Anticancer agent Halaven	3.4	12.8	3.5	103.4 <92.7>
Antiepileptic agent Fycompa	2.2	9.2	2.8	129.2 <119.7>
Antiepileptic agent Inovelon	0.7	2.7	0.7	110.7 <103.8>

* YOY percentage: figures shown in angle brackets "< >" exclude the effects of foreign exchange fluctuations.

5) Asia and Latin America pharmaceutical business

(billions of yen)

	FY 2021		FY 2022	
	Q1	Full year	Q1	YOY (%)
Revenue	12.6	48.6	12.0	95.0 <86.4>
Segment profit	5.7	20.4	5.3	94.0 <85.3>
Asia and Latin America - revenue from major products				
Alzheimer's disease / Dementia with Lewy bodies treatment Aricept	3.0	11.8	3.3	109.9 <102.3>
Anticancer agent Lenvima	1.7	7.9	2.3	134.3 <121.0>
Proton pump inhibitor Pariet	1.2	4.0	1.1	90.9 <82.7>
Anticancer agent Halaven	0.6	2.3	0.8	133.0 <117.7>
Peripheral neuropathy treatment Methycobal	0.8	3.5	0.8	90.3 <80.8>
Antiepileptic agent Fycompa	0.3	1.5	0.4	119.5 <108.9>

* YOY percentage: figures shown in angle brackets "< >" exclude the effects of foreign exchange fluctuations.

* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan, the Philippines and Thailand.

6) OTC and Others (Japan)

(billions of yen)

	FY 2021		FY 2022	
	Q1	Full year	Q1	YOY (%)
Revenue	5.2	23.8	6.0	115.3
Segment profit	0.7	4.7	1.4	207.8
OTC and others, revenue from major products				
Vitamin B2 preparation, "Chocola BB Plus," etc. Chocola BB Group	3.5	14.3	3.9	111.3

4. Revenue from Major Products

1) Neurology Products

(billions of yen)

	FY 2021		FY 2022	
	Q1	Full year	Q1	YOY (%)
Neurology Products Total	34.1	135.6	37.1	108.8 <97.6>
Fycompa (Antiepileptic agent)	7.4	31.9	9.9	133.1 <119.4>
Japan	1.2	5.4	1.6	126.0
Americas	3.4	14.6	4.6	132.6 <112.2>
China	0.2	1.2	0.6	234.9 <203.4>
EMEA	2.2	9.2	2.8	129.2 <119.7>
Asia and Latin America	0.3	1.5	0.4	119.5 <108.9>
Methycobal (Peripheral neuropathy treatment)	6.8	28.1	8.2	121.2 <111.3>
Japan	2.4	10.8	2.7	111.5
China	3.3	12.7	4.4	132.8 <115.0>
Asia and Latin America	0.8	3.5	0.8	90.3 <80.8>
Dayvigo (Insomnia treatment)	2.6	16.4	6.5	247.1 <240.4>
Japan	1.9	12.7	5.3	285.2
Americas	0.8	3.7	1.1	147.4 <125.6>
Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)	6.3	24.4	6.3	98.7 <91.6>
Japan	1.8	6.9	1.2	69.4
China	1.4	5.3	1.6	113.1 <98.0>
Asia and Latin America	3.0	11.8	3.3	109.9 <102.3>
Inovelon/Banzel (Antiepileptic agent)	3.7	10.3	1.8	48.7 <43.7>
Americas	2.8	7.0	0.9	30.6 <25.9>
EMEA	0.7	2.7	0.7	110.7 <103.8>
Other	7.3	24.5	4.5	61.7 <60.3>

* YOY percentage: figures shown in angle brackets "< >" exclude the effects of foreign exchange fluctuations.

* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan, the Philippines and Thailand.

2) Oncology Products

(billions of yen)

	FY 2021		FY 2022	
	Q1	Full year	Q1	YOY (%)
Oncology Products Total	56.1	238.5	79.7	142.1 <124.1>
Lenvima/Kispplx (Anticancer agent)	44.2	192.3	66.3	150.0 <130.4>
Japan	2.5	10.3	3.6	144.3
Americas	24.4	116.5	38.5	157.8 <133.4>
China	10.8	35.8	13.9	128.5 <111.3>
EMEA	4.8	21.8	8.1	167.1 <153.8>
Asia and Latin America	1.7	7.9	2.3	134.3 <121.0>
Halaven (Anticancer agent)	10.2	39.4	11.1	109.7 <98.3>
Japan	2.0	8.3	2.2	113.6
Americas	3.3	14.3	4.1	124.7 <105.5>
China	0.9	1.6	0.6	58.5 <50.6>
EMEA	3.4	12.8	3.5	103.4 <92.7>
Asia and Latin America	0.6	2.3	0.8	133.0 <117.7>
Other	1.7	6.8	2.2	130.9 <116.3>

* YOY percentage: figures shown in angle brackets "< >" exclude the effects of foreign exchange fluctuations.

5. Revenue Forecast by Reporting Segment (FY 2022)

(billions of yen)

	FY 2021		FY 2022	
	Q1	Full year	Q1	Full year forecast
Japan (Prescription Medicines)	49.6	214.0	57.5	201.0
Fully human anti-TNF-α monoclonal antibody Humira	11.4	50.6	12.6	41.5
Insomnia treatment Dayvigo	1.9	12.7	5.3	18.0
Anticancer agent Lenvima	2.5	10.3	3.6	13.5
Peripheral neuropathy treatment Methycobal	2.4	10.8	2.7	9.0
Anticancer agent Halaven	2.0	8.3	2.2	8.5
Chronic constipation treatment Goofice [#]	1.4	6.1	1.7	7.0
Antiepilepsy agent Fycompa	1.2	5.4	1.6	6.5
Elemental diet Elental [#]	1.7	6.8	1.8	6.5
Proton pump inhibitor Pariet [#]	1.7	7.1	1.6	6.0
Chronic constipation treatment Movicol [#]	1.1	4.9	1.6	5.5
Americas	38.3	172.0	53.1	198.5
United States	37.7	169.5	52.2	195.5
China	27.4	108.4	34.8	97.5
EMEA	14.1	59.3	18.1	59.5
Asia and Latin America	12.6	48.6	12.0	45.5
OTC and others (Japan)	5.2	23.8	6.0	24.5
Vitamin B2 preparation, "Chocola BB Plus," etc. Chocola BB Group	3.5	14.3	3.9	14.5
Other	51.7	129.9	2.9	73.5
Consolidated revenue	198.9	756.2	184.3	700.0
Global revenue from major products				
Lenvima/Kisplyx	44.2	192.3	66.3	218.0
Japan	2.5	10.3	3.6	13.5
Americas	24.4	116.5	38.5	145.5
China	10.8	35.8	13.9	23.5
EMEA	4.8	21.8	8.1	26.5
Asia and Latin America	1.7	7.9	2.3	9.0
Halaven	10.2	39.4	11.1	38.0
Japan	2.0	8.3	2.2	8.5
Americas	3.3	14.3	4.1	11.5
China	0.9	1.6	0.6	2.0
EMEA	3.4	12.8	3.5	13.0
Asia and Latin America	0.6	2.3	0.8	3.0
Fycompa	7.4	31.9	9.9	37.5
Japan	1.2	5.4	1.6	6.5
Americas	3.4	14.6	4.6	17.5
China	0.2	1.2	0.6	2.0
EMEA	2.2	9.2	2.8	10.0
Asia and Latin America	0.3	1.5	0.4	1.5
Dayvigo	2.6	16.4	6.5	27.0
Japan	1.9	12.7	5.3	18.0
Americas	0.8	3.7	1.1	9.0

[#] EA Pharma product

6. Consolidated Statement of Comprehensive Income

(billions of yen)

	FY 2021		FY 2022		
	Q1	Full year	Q1	YOY (%)	Diff.
Profit for the period	42.3	45.7	28.0	66.2	(14.3)
Other comprehensive income (loss)					
Items that will not be reclassified to profit or loss					
Financial assets measured at fair value through other comprehensive income (loss)	(1.2)	(0.8)	2.7	—	3.9
Remeasurements of defined benefit plans	—	(1.1)	—	—	—
Subtotal	(1.2)	(1.9)	2.7	—	3.9
Items that may be reclassified subsequently to profit or loss					
Exchange differences on translation of foreign operations	1.3	46.9	49.0	3858.9	47.7
Cash flow hedges	0.0	0.1	(0.0)	—	(0.0)
Subtotal	1.3	47.0	49.0	3800.6	47.7
Total other comprehensive income (loss), net of tax	0.1	45.1	51.7	46244.7	51.6
Comprehensive income (loss) for the period	42.4	90.8	79.7	188.1	37.3
Comprehensive income (loss) for the period attributable to					
Owners of the parent	42.2	93.0	78.6	186.2	36.4
Non-controlling interests	0.1	(2.2)	1.1	763.9	1.0

7. Consolidated Statement of Cash Flows

(billions of yen)

	FY 2021	FY 2022	
	Q1	Q1	Diff.
Operating activities			
Profit before income taxes	55.7	9.7	(46.0)
Depreciation and amortization	9.3	9.8	0.5
(Increase) decrease in working capital	(63.3)	(1.1)	62.3
Interest and dividends received	0.7	0.7	(0.0)
Interest paid	(0.3)	(0.3)	(0.0)
Income taxes paid	(2.3)	(4.5)	(2.3)
Other	(14.3)	(10.3)	4.0
Net cash from (used in) operating activities	(14.5)	3.9	18.4
Investing activities			
Purchases of property, plant and equipment	(12.1)	(11.6)	0.5
Purchases of intangible assets	(2.5)	(4.3)	(1.7)
Proceeds from sale of property, plant and equipment and intangible assets	13.3	0.2	(13.1)
Purchases of financial assets	(0.5)	(0.9)	(0.4)
Proceeds from sale and redemption of financial assets	2.2	0.0	(2.2)
Subtotal <Capital expenditures (cash basis)>	0.4	(16.6)	(16.9)
Payments of time deposits exceeding three months	(0.0)	(0.0)	0.0
Other	(0.0)	(0.3)	(0.2)
Net cash from (used in) investing activities	0.3	(16.8)	(17.2)
Financing activities			
Net increase (decrease) in short-term borrowings	2.8	—	(2.8)
Repayments of long-term borrowings	—	(0.0)	(0.0)
Repayments of lease liabilities	(2.5)	(2.4)	0.2
Dividends paid	(22.9)	(22.9)	(0.0)
Other	0.2	0.1	(0.1)
Net cash from (used in) financing activities	(22.5)	(25.2)	(2.7)
Effect of exchange rate change on cash and cash equivalents	1.0	16.3	15.3
Net increase (decrease) in cash and cash equivalents	(35.7)	(21.8)	13.8
Cash and cash equivalents at beginning of period	248.7	309.6	60.9
Cash and cash equivalents at end of period	213.1	287.8	74.7
Free cash flows	(14.1)	(12.6)	1.5

* "Free cash flows" = "Net cash from (used in) operating activities" - "Capital expenditures (cash basis)"

Notes

■ Net cash from (used in) investing activities

Capital expenditures occurred due to additional investment in research facilities and manufacturing facilities

■ Net cash from (used in) financing activities

Dividends were paid

8. Capital Expenditures, Depreciation and Amortization

(billions of yen)

	FY 2021		FY 2022		FY 2022
	Q1	Full year	Q1	Diff.	Full year (est.)
Capital expenditures (cash basis)	14.7	40.5	15.9	1.2	50.0
Property, plant and equipment	12.1	29.0	11.6	(0.5)	28.5
Intangible assets	2.5	11.4	4.3	1.7	21.5
Depreciation and amortization	9.3	38.4	9.8	0.5	39.5
Property, plant and equipment	5.3	21.8	5.6	0.3	22.0
Intangible assets	4.0	16.6	4.2	0.2	17.5

9. Consolidated Statement of Financial Position

<Assets>

(billions of yen)

	FY 2021		FY 2022			
	March 31, 2022	Ratio (%)	June 30, 2022	Ratio (%)	% change	Diff.
Assets						
Non-current assets						
Property, plant and equipment	169.9	13.7	172.9	13.6	101.8	3.0
Goodwill	191.8	15.5	213.8	16.8	111.5	22.0
Intangible assets	95.5	7.7	93.9	7.4	98.4	(1.5)
Other financial assets	44.0	3.6	49.2	3.9	111.8	5.2
Other assets	20.9	1.7	20.7	1.6	99.0	(0.2)
Deferred tax assets	76.6	6.2	101.4	8.0	132.3	24.8
Total non-current assets	598.7	48.3	651.9	51.2	108.9	53.2
Current assets						
Inventories	99.0	8.0	103.5	8.1	104.5	4.5
Trade and other receivables	207.9	16.8	198.9	15.6	95.7	(9.0)
Other financial assets	0.4	0.0	2.6	0.2	611.4	2.2
Other assets	23.6	1.9	28.0	2.2	118.9	4.5
Cash and cash equivalents	309.6	25.0	287.8	22.6	93.0	(21.8)
Total current assets	640.6	51.7	620.9	48.8	96.9	(19.7)
Total assets	1,239.3	100.0	1,272.9	100.0	102.7	33.6

Notes

■ Assets	
(Deferred tax assets)	Increase due to recognition of losses on transferring of investments in subsidiaries for tax purposes following a repayment of paid-in capital from a U.S. subsidiary to the Company as part of the Group's capital policy to optimize the global allocation of cash
(Cash and cash equivalents)	Decrease mainly due to payment of dividends

<Equity and Liabilities>

(billions of yen)

	FY 2021		FY 2022			
	March 31, 2022	Ratio (%)	June 30, 2022	Ratio (%)	% change	Diff.
Equity						
Equity attributable to owners of the parent						
Share capital	45.0	3.6	45.0	3.5	100.0	—
Capital surplus	77.6	6.3	77.6	6.1	100.0	(0.0)
Treasury shares	(33.9)	(2.7)	(33.9)	(2.7)	99.9	0.0
Retained earnings	506.6	40.9	513.3	40.3	101.3	6.7
Other components of equity	153.6	12.4	202.5	15.9	131.9	49.0
Total equity attributable to owners of the parent	748.8	60.4	804.5	63.2	107.4	55.7
Non-controlling interests	22.7	1.8	23.8	1.9	104.8	1.1
Total equity	771.5	62.3	828.3	65.1	107.4	56.8
Liabilities						
Non-current liabilities						
Borrowings	94.9	7.7	84.9	6.7	89.5	(10.0)
Other financial liabilities	39.2	3.2	38.3	3.0	97.8	(0.9)
Provisions	1.5	0.1	1.5	0.1	102.6	0.0
Other liabilities	18.4	1.5	17.1	1.3	93.2	(1.3)
Deferred tax liabilities	0.5	0.0	0.7	0.1	151.0	0.2
Total non-current liabilities	154.4	12.5	142.6	11.2	92.3	(11.8)
Current liabilities						
Borrowings	—	—	10.0	0.8	—	10.0
Trade and other payables	108.1	8.7	96.1	7.6	88.9	(12.0)
Other financial liabilities	40.9	3.3	42.3	3.3	103.6	1.5
Income taxes payable	6.9	0.6	9.0	0.7	131.4	2.2
Provisions	17.9	1.4	21.9	1.7	122.1	4.0
Other liabilities	139.6	11.3	122.5	9.6	87.8	(17.1)
Total current liabilities	313.3	25.3	301.9	23.7	96.3	(11.4)
Total liabilities	467.8	37.7	444.5	34.9	95.0	(23.3)
Total equity and liabilities	1,239.3	100.0	1,272.9	100.0	102.7	33.6

Notes

<p>■ Equity (Other components of equity)</p>	Increase in exchange differences on translation of foreign operations due to depreciation of yen
<p>■ Liabilities (Borrowings - current / non-current) (Trade and other payables) (Other financial liabilities - current)</p>	<p>Reclassification of non-current liabilities to current liabilities Decrease mainly in accounts payable - others to partners Decrease mainly in accrued expenses</p>

10. Changes in Quarterly Results

1) Income Statement

(billions of yen)

	FY 2021				FY 2022
	Q1	Q2	Q3	Q4	Q1
Revenue	198.9	163.5	203.0	190.9	184.3
Cost of sales	39.2	40.6	44.2	50.7	47.4
Gross profit	159.6	122.8	158.8	140.2	136.9
Selling, general and administrative expenses	74.8	79.9	101.5	110.3	92.3
Selling expenses	32.4	40.3	53.7	64.0	50.2
Personnel expenses	22.7	22.9	28.3	27.4	24.0
Administrative and other expenses	19.7	16.6	19.5	18.9	18.1
Research and development expenses	41.8	38.1	43.4	48.5	38.5
Other income	13.4	0.2	0.4	0.5	2.5
Other expenses	1.1	(0.3)	0.7	2.6	1.1
Operating profit	55.3	5.4	13.6	(20.6)	7.4
Financial income	0.7	0.5	0.6	0.5	2.7
Financial costs	0.4	0.4	0.4	0.5	0.4
Profit before income taxes	55.7	5.4	13.9	(20.6)	9.7
Income taxes	13.5	1.3	0.8	(6.9)	(18.2)
Profit for the period	42.3	4.1	13.0	(13.7)	28.0
Profit for the period attributable to					
Owners of the parent	42.1	3.9	14.2	(12.2)	26.9
Non-controlling interests	0.1	0.2	(1.1)	(1.5)	1.1
Comprehensive income for the period	42.4	7.9	26.2	14.3	79.7
Earnings per share (EPS, yen)	146.89	13.72	49.39	(42.72)	93.81

* EPS: Earnings Per Share attributable to owners of the parent (basic).

2) Cash Flows

(billions of yen)

	FY 2021				FY 2022
	Q1	Q2	Q3	Q4	Q1
Net cash from (used in) operating activities	(14.5)	82.4	4.6	45.1	3.9
Net cash from (used in) investing activities	0.3	(7.8)	(10.5)	(10.9)	(16.8)
Net cash from (used in) financing activities	(22.5)	(5.4)	(25.5)	4.5	(25.2)
Cash and cash equivalents at the end of period	213.1	283.0	258.4	309.6	287.8
Free cash flow	(14.1)	74.6	(5.9)	34.1	(12.6)

* "Free cash flow" = "Net cash from (used in) operating activities" - "Capital expenditures (cash basis)"

3) Capital Expenditures, Depreciation and Amortization

(billions of yen)

	FY 2021				FY 2022
	Q1	Q2	Q3	Q4	Q1
Capital expenditures (cash basis)	14.7	6.8	10.4	8.6	15.9
Property, plant and equipment	12.1	6.1	3.8	7.0	11.6
Intangible assets	2.5	0.7	6.6	1.6	4.3
Depreciation and amortization	9.3	9.7	9.7	9.7	9.8
Property, plant and equipment	5.3	5.5	5.5	5.5	5.6
Intangible assets	4.0	4.2	4.2	4.2	4.2

4) Financial Positions

(billions of yen)

	Jun. 30, 2021	Sept. 30, 2021	Dec. 31, 2021	Mar. 31, 2022	Jun. 30, 2022
Total assets	1,127.7	1,138.4	1,165.6	1,239.3	1,272.9
Equity	745.7	753.6	756.9	771.5	828.3
Attributable to owners of the parent	720.9	728.6	733.0	748.8	804.5
Liabilities	382.0	384.8	408.7	467.8	444.5
Borrowings	92.7	89.9	89.9	94.9	94.9
Ratio of equity attributable to owners of the parent (%)	63.9	64.0	62.9	60.4	63.2
Net debt equity ratio (times)	(0.20)	(0.30)	(0.26)	(0.32)	(0.28)

* "Net debt equity ratio (Net DER)" = ("Interest-bearing debt" ("Borrowings") - "Cash and cash equivalents" -

"Time deposits exceeding three months, etc." - "Investment securities held by the parent") / "Equity attributable to owners of the parent"

5) Changes in Quarterly Revenue from Major Products

(1) Neurology Products

(billions of yen)

	FY 2021				FY 2022
	Q1	Q2	Q3	Q4	Q1
Neurology Total	34.1	33.3	36.1	32.2	37.1
Fycompa (Antiepileptic agent)	7.4	7.7	8.4	8.3	9.9
Japan	1.2	1.4	1.5	1.3	1.6
Americas	3.4	3.5	3.8	3.8	4.6
China	0.2	0.3	0.3	0.4	0.6
EMEA	2.2	2.2	2.4	2.5	2.8
Asia and Latin America	0.3	0.4	0.4	0.4	0.4
Methycobal (Peripheral neuropathy treatment)	6.8	7.3	7.7	6.4	8.2
Japan	2.4	2.8	2.9	2.5	2.7
China	3.3	3.3	3.3	2.7	4.4
Asia and Latin America	0.8	0.9	0.9	0.8	0.8
Dayvigo (Insomnia treatment)	2.6	3.7	5.0	5.1	6.5
Japan	1.9	2.9	3.9	4.1	5.3
Americas	0.8	0.8	1.1	1.0	1.1
Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)	6.3	6.1	6.5	5.5	6.3
Japan	1.8	1.9	1.9	1.3	1.2
China	1.4	1.2	1.5	1.1	1.6
Asia and Latin America	3.0	2.9	3.0	2.9	3.3
Inovelon/Banzel (Antiepileptic agent)	3.7	2.6	2.4	1.6	1.8
Americas	2.8	1.8	1.5	0.8	0.9
EMEA	0.7	0.7	0.7	0.7	0.7
Other	7.3	5.8	6.1	5.3	4.5

* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan, the Philippines and Thailand.

(2) Oncology Products

(billions of yen)

	FY 2021				FY 2022
	Q1	Q2	Q3	Q4	Q1
Oncology Total	56.1	59.1	60.8	62.5	79.7
Lenvima/Kispplx (Anticancer agent)	44.2	47.6	49.3	51.2	66.3
Japan	2.5	2.6	2.6	2.6	3.6
Americas	24.4	26.9	31.3	33.8	38.5
China	10.8	10.5	7.1	7.4	13.9
EMEA	4.8	5.1	6.3	5.5	8.1
Asia and Latin America	1.7	2.4	2.0	1.8	2.3
Halaven (Anticancer agent)	10.2	9.8	9.8	9.7	11.1
Japan	2.0	2.1	2.2	2.0	2.2
Americas	3.3	3.6	3.6	3.9	4.1
China	0.9	0.3	0.0	0.3	0.6
EMEA	3.4	3.0	3.4	3.0	3.5
Asia and Latin America	0.6	0.6	0.5	0.6	0.8
Other	1.7	1.8	1.7	1.6	2.2

11. Major R&D Pipeline

(1) Neurology

Development Code: E2007 Generic Name: perampanel Product Name: Fycompa				In-house
Indications / Drug class: Antiepileptic agent / AMPA receptor antagonist				Oral
Description: Selectively inhibits the AMPA receptor (a glutamate receptor subtype) activation by glutamate. Approved as an adjunctive therapy for partial-onset seizures in over 70 countries including Japan, the United States, China and countries in Europe and in Asia. Approved for monotherapy and adjunctive use in the treatment of partial onset seizures (with or without secondarily generalized seizures) in patients 4 years of age and older in Japan, the United States and China. Approved for adjunctive use in the treatment of partial onset seizures (with or without secondarily generalized seizures) in patients 4 years of age and older in Europe. Also approved as an adjunctive therapy for primary generalized tonic-clonic seizures in over 70 countries including Japan, the United States, and countries in Europe and in Asia. Approved for an adjunctive therapy for primary generalized tonic-clonic seizures in patients 7 years of age and older in Europe, and 12 years of age and older in Japan and United States. An oral suspension formulation has been approved in the United States and Europe. A fine granule formulation has been approved in Japan.				
Lennox-Gastaut syndrome (Additional Indication)	Study 338	JP/US/EU		PIII

Development Code: E2006 Generic Name: lemborexant Product Name: Dayvigo				In-house
Indications / Drug class: Insomnia treatment / Orexin receptor antagonist				Oral
Description: An orexin receptor antagonist that blocks the receptors involved in the regulation of sleep and wakefulness. It is expected to alleviate wakefulness, thereby facilitating faster onset and maintenance of sleep. It has been approved for the treatment of insomnia in over 10 countries including Japan, the United States and countries in Asia. In addition, development for irregular sleep-wake rhythm disorder and Alzheimer's disease dementia is ongoing.				
Insomnia disorder	Study 311	CH		PIII
Irregular sleep-wake rhythm disorder and Alzheimer's disease dementia (Additional Indication)	Study 202	JP/US		PII

Development Code: BAN2401 Generic Name: lecanemab				In-license (BioArctic AB)
Indications / Drug class: Disease modifying treatment for Alzheimer's disease / anti-A β protofibril antibody				Injection
Description: An IgG1 antibody that targets amyloid beta (A β) protofibrils. Expected to be effective in the treatment of Alzheimer's disease (AD) by slowing disease progression through the elimination of neurotoxic A β protofibrils. The Phase III clinical study Clarity AD in patients with mild cognitive impairment due to AD or mild AD (collectively known as early AD) is underway. Studies to determine new dosing regimen after removal of brain A β is also underway. In addition, developing subcutaneous injection formulation is underway in order to increase convenience. The Phase III clinical study AHEAD 3-45 for preclinical (asymptomatic) AD is underway in collaboration with the Alzheimer's Clinical Trials Consortium (ACTC). The United States Food and Drug Administration (FDA) granted Breakthrough Therapy designation and Fast Track designation. In July 2022, the Biological License Application was accepted by the FDA, under the accelerated approval pathway. Submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system has been initiated in Japan with the aim of obtaining early approval. Joint development with Biogen Inc.				
Early AD	Study 201	US	⊙	Submission for accelerated approval (accepted: July 2022)
	Study 301 (Clarity AD)	JP/US/EU/CH		PIII
Preclinical AD	Study 303 (AHEAD 3-45)	JP/US/EU		PIII

Development Code: E2023 Generic Name: lorcaserin				In-license (Arena Pharmaceuticals)
Indications / Drug class: Treatment for Dravet syndrome / serotonin 2C receptor agonist				Oral
Description: By selectively activating serotonin 2C receptors in the brain, through the activation GABAergic inhibitory interneuron, expected to suppress seizure of Dravet syndrome by increasing synaptic suppression from GABAergic. Although approval for the obesity indication has been voluntarily withdrawn, due to the request from Dravet syndrome patient groups, the extended access program has been continued in the United States, and the Phase III clinical study is underway for this indication. FDA has designated it as an orphan drug for Dravet syndrome.				
Dravet syndrome	Study 304	US		PIII

JP: Japan, US: the United States, EU: Europe, CH: China, P: (Clinical trial) Phase

⊙ : Development progress from April 2022 onwards

Development Code: E2027				In-house
Indications / Drug class: Treatment for dementia with Lewy bodies, Parkinson's disease dementia / PDE9 inhibitor				Oral
Description: A selective phosphodiesterase (PDE) 9 inhibitor that reduces the degradation of cyclic GMP, which is critical to signal transduction among cells. Expected to be a new treatment for dementia with Lewy bodies and Parkinson's disease dementia by helping to maintain the concentration of cyclic GMP in the brain.				
Dementia with Lewy bodies, Parkinson's disease dementia	Study 203	US		PII

Development Code: E2730				In-house
Indications / Drug class: Antiepileptic agent, treatment for neurological diseases / synapse function modulator				Oral
Description: A compound with a novel mechanism of action that selectively regulates the function of activated synapses. Expected to be a new treatment for neurological diseases such as epilepsy, including orphan epilepsy, and epileptogenesis.				
Epilepsy	Study 201	US		PII

Development Code: E2814				Collaboration (University College London)
Indications / Drug class: anti-MTBR tau antibody				Injection
Description: An anti-microtubule binding region (MTBR) tau antibody that was discovered as part of the research collaboration between Eisai and University College London. Expected to prevent the spreading of tau seeds within the brain. Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) has selected E2814 as the first investigational medicine among anti-tau drugs for their DIAN-TU tau study, and Phase Ib/II study and Phase II/III study Tau NexGen for dominantly inherited AD have been initiated.				
Alzheimer's disease	Tau NexGen study Study103	US US/EU		PII/III PI/II

Development Code: E2511				In-house
Indications / Drug class: Synapse regenerant				Oral
Description: Expected to promote recovery and synaptic remodeling of damaged cholinergic neurons, and to suppress cerebral atrophy caused by neurodegeneration.				
Alzheimer's disease	—	US		PI

Development Code: EA4017		In-house	Oral
Chemotherapy-induced peripheral neuropathy (Development conducted by EA Pharma)	—	JP	PI

(2) Oncology

Development Code: E7080 Generic Name: lenvatinib Product Name: Lenvima				In-house
Indications / Drug class: Anticancer agent / kinase inhibitor				Oral
Description: An orally available multiple kinase inhibitor that selectively inhibits kinase activities vascular endothelial growth factor receptors (VEGFR): VEGFR1, VEGFR2 and VEGFR3, and fibroblast growth factor receptors (FGFR): FGFR1,FGFR2, FGFR3 and FGFR4, in addition to pathogenic angiogenesis, tumor growth and cancer progression related receptor tyrosine kinases such as the platelet derived growth factor receptor alpha (PDGFR α), KIT, and RET. Discovered and developed in-house. As monotherapy indications, approved for use in the treatment of thyroid cancer in over 80 countries including Japan, the United States, China and countries in Europe and in Asia. Approved for use in the treatment of hepatocellular carcinoma (first-line) in over 80 countries including in Japan, the United States, China and countries in Europe and in Asia. Also approved for use in the treatment of thymic carcinoma in Japan. As indication in combination with everolimus, approved for use in the treatment of renal cell carcinoma (second-line) in over 65 countries including the United States, countries in Europe and in Asia. As for the combination therapy with pembrolizumab, approved for use in the treatment of renal cell carcinoma in over 40 countries including in Japan, the United States, and countries in Europe and in Asia, and approved for use in the treatment of endometrial carcinoma in over 45 countries including in Japan, the United States, and countries in Europe and in Asia, including conditional approval. The agent is marketed under the product name Kisplyx only for renal cell carcinoma indication in Europe. Joint development with Merck & Co., Inc., Rahway, NJ, USA, through an affiliate.				
In combination with anti-PD-1 antibody pembrolizumab, joint development with Merck & Co., Inc., Rahway, NJ, USA, through an affiliate (Additional Indication)				
Endometrial carcinoma / First-line	LEAP-001	JP/US/EU/CH		P/III
Hepatocellular carcinoma / First-line	LEAP-002	JP/US/EU/CH		P/III
Melanoma / First-line	LEAP-003	US/EU/CH		P/III
Non-small cell lung cancer (nonsquamous) (in combination with chemotherapy) / First-line	LEAP-006	JP/US/EU/CH		P/III
Non-small cell lung cancer / Second-line	LEAP-008	JP/US/EU		P/III
Head and neck cancer / First-line	LEAP-010	JP/US/EU/CH		P/III
Hepatocellular carcinoma (in combination with transcatheter arterial chemoembolization) / First-line	LEAP-012	JP/US/EU/CH		P/III
Esophageal carcinoma (in combination with chemotherapy) / First-line	LEAP-014	JP/US/EU/CH		P/III
Gastric cancer (in combination with chemotherapy) / First-line	LEAP-015	JP/US/EU/CH		P/III
Colorectal cancer (non MSI-H / pMMR) / Third-line	LEAP-017	US/EU		P/III
Melanoma / Second-line	LEAP-004	US/EU		P/II
Selected solid tumors (Gastric cancer, colorectal cancer, glioblastoma, biliary tract cancers and pancreatic cancer)	LEAP-005	US/EU		P/II
Head and neck cancer / Second-line	LEAP-009	US/EU		P/II
Selected solid tumors (Endometrial carcinoma, renal cell carcinoma, head and neck cancer, bladder cancer, non-small cell lung cancer and melanoma)	Study 111 —	US/EU JP		P/II PI
In combination with anticancer agent everolimus, joint development with Merck & Co., Inc., Rahway, NJ, USA, through an affiliate (Additional Indication)				
Renal cell carcinoma / First-line	Study 307	JP/US/EU		P/III
In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Indication)				
Hepatocellular carcinoma	—	JP		PI

JP: Japan, US: the United States, EU: Europe, CH: China, P: (Clinical trial) Phase

© : Development progress from April 2022 onwards

Development Code: E7389 Generic Name: eribulin Product Name: Halaven				In-house
Indications / Drug class: Anticancer agent / microtubule dynamics inhibitor				Injection
Description: A synthetic analog of halichondrin B derived from the marine sponge <i>Halichondria okadae</i> . Shows an antitumor effect by arresting the cell cycle through inhibition of the growth of microtubules. Approved in over 80 countries including Japan, the United States, China and countries in Europe and in Asia for use in the treatment of breast cancer. Approved in over 80 countries including Japan, the United States and countries in Europe and in Asia for use in the treatment of liposarcoma (soft tissue sarcoma in Japan).				
Monotherapy (Additional Formulation)				
Liposomal formulation	—	JP/EU		PI
In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Formulation)				
Liposomal formulation	Study 120	JP		PI/II

Development Code: H3B-6545				In-house
Indications / Drug class: Anticancer agent / ER α inhibitor				Oral
Description: An orally administered selective estrogen receptor (ER) α covalent antagonist that inhibits ER α wild type / ER α mutant. Expected to show an antitumor effect against ER positive / HER2 negative breast cancers.				
Breast cancer	Study 101	US/EU		PI/II
Breast cancer (in combination with CDK4/6 inhibitor palbociclib)	—	US/EU		PI

Development Code: E7090 Generic Name: tasurgratinib				In-house
Indications / Drug class: Anticancer agent / FGFR1, FGFR2, FGFR3 inhibitor				Oral
Description: An orally administered fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor. Phase II clinical study for unresectable cholangiocarcinoma (one of biliary tract cancers) with <i>FGFR2</i> gene fusion is ongoing. It has been granted the orphan drug designation with a prospective indication for unresectable biliary tract cancer with <i>FGFR2</i> gene fusion by the Ministry of Health, Labour and Welfare (MHLW) in Japan.				
Cholangiocarcinoma	Study 201	JP/CH		PII
Breast cancer	—	JP		PI

Development Code: MORAb-202 Generic Name: farletuzumab ecteribulin				In-house
Indications / Drug class: Anticancer agent / Folate receptor α targeted antibody drug conjugate				Injection
Description: An antibody drug conjugate (ADC) with approved anticancer drug eribulin. Expected to show an antitumor effect against folate receptor α -positive tumors by concentrating eribulin on tumor; inclusive of endometrial, ovarian, lung and breast cancers. Joint development with Bristol Myers Squibb.				
Solid tumors	—	US		PI/II
Solid tumors	—	JP		PI

Development Code: E7386				Collaboration (PRISM BioLab)
Indications / Drug class: Anticancer agent / CBP/ β -catenin inhibitor				Oral
Description: A CREB-binding protein (CBP) / β -catenin inhibitor that blocks the protein-protein interaction between CBP and β -catenin, and regulates Wnt signaling-dependent gene expression. Expected inhibition of Wnt signaling-dependent tumor growth.				
Solid tumors (in combination with pembrolizumab)	Study 201	JP/US/EU	⊙	PI/II
Solid tumors	—	JP/EU		PI
Solid tumors (in combination with lenvatinib)	—	JP		PI

JP: Japan, US: the United States, EU: Europe, CH: China, P: (Clinical trial) Phase

⊙ : Development progress from April 2022 onwards

Development Code: H3B-6527		In-house		Oral
Hepatocellular carcinoma	—	US/EU	PI	
Development Code: E7130		Collaboration (Harvard University)		Injection
Solid tumors	—	JP	PI	
Development Code: E7766		In-house		Injection
Solid tumors	—	US/EU	PI	

(3) Gastrointestinal Disorders

Development Code: E3112		In-house		Injection
Liver disease (Development conducted by EA Pharma)	—	JP	PI	
Development Code: AJM347		In-house		Oral
Inflammatory bowel disease (Development conducted by EA Pharma)	—	EU	PI	
Development Code: EA1080		In-house		Oral
Inflammatory bowel disease (Development conducted by EA Pharma)	—	EU	PI	
Development Code: EA3571		In-house		Oral
Nonalcoholic steatohepatitis (Development conducted by EA Pharma)	—	JP	PI	

(4) Other

Development Code: FYU-981 Generic Name: dotinurad			In-license (FUJI YAKUHIN)	
Indications / Drug class: Treatment for Hyperuricemia and Gout / selective URAT1 inhibitor			Oral	
Description: Dotinurad selectively inhibits URAT1, one of the uric acid transporters, thus preventing reabsorption of uric acid by kidneys and promoting uric acid excretion in urine. In addition, it has a small effect on other transporters affecting uric acid secretion, so it reduces serum uric acid levels at lower doses. Therefore, dotinurad is expected to have a low risk of side effects and drug interaction. In Japan, FUJI YAKUHIN obtained manufacturing and marketing approval for dotinurad in January 2020. Eisai entered into a license agreement concerning the development and distribution in China in February 2020, and in five ASEAN countries in August 2021 with FUJI YAKUHIN.				
Gout	Study 301	CH	PIII	
Development Code: E6742			In-house	
Indications / Drug class: Treatment for Systemic lupus erythematosus / TLR 7/8 inhibitor			Oral	
Description: Toll-Like Receptors (TLRs) are receptors of the innate immune system, and activated TLRs initiate an inflammatory reaction or an antiviral response. E6742 is the inhibitor of oral and selective TLR7/8 which is associated with the pathogenesis of systemic lupus erythematosus. This project has been selected by the Japan Agency for Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) grand program.				
Systemic lupus erythematosus	Study 101	JP	PI/II	
Development Code: E8001		In-house		Injection
Rejection reaction associated with organ transplantation	—	JP	PI	

© Phase III REMAP-COVID study of eritoran for suppression for increasing of severity of COVID-19 in Japan and the U.S. was discontinued, therefore has been removed from this list.